TransMedics Group, Inc. (TMDX) saw its stock price soar 6.15% in the after-hours trading session on Monday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.

In a statement, TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, diverse culture, and steadfast focus on delivering exceptional products and services for organ transplantation. The company defended the integrity of its practices, world-class team, compliance with applicable laws, and unwavering commitment to improving clinical outcomes.

TransMedics highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to confidently utilize donor organs that would have otherwise been unutilized due to historical technology and logistics limitations. The company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set.